NEW YORK (360Dx) – HTG Molecular disclosed in a filing with the US Securities and Exchange Commission that it has entered into a statement of work with Qiagen Manchester, a UK-based subsidiary of Qiagen, pursuant to a previously announced master assay development, commercialization, and manufacturing agreement.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.